Skip to main content
    C

    Collegium Pharmaceutical Inc (COLL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $25.43
    +0.11 (+0.43%)

    Market Cap: $786.83M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Collegium Pharmaceutical Inc (COLL) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Collegium Pharmaceutical (COLL) to earn $7.48 per share in the fiscal year ending Dec 31, 2026, on revenue of $831.97M. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $7.16.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.

    RatingAnalystsShare
    Strong Buy225.0%
    Buy562.5%
    Hold112.5%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 4.3% and revenue estimates rise 1.9%.

    Fiscal year ending Dec 31, 2026
    $7.48
    EPS consensus, revenue $831.97M
    Fiscal year ending Dec 31, 2027
    $7.16
    EPS consensus, revenue $847.70M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$7.48$7.30 to $7.607$831.97M$826.10M to $834.00M7
    Dec 31, 2027$7.16$5.06 to $8.167$847.70M$748.50M to $888.10M7

    Quarterly Estimates

    The EPS consensus falls from $2.03 for the quarter ending Dec 31, 2026 to $1.62 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.03$1.86 to $2.1510$226.07M$212.07M to $235.52M9
    Mar 31, 2027$1.62$1.25 to $1.845$200.74M$185.10M to $206.41M4

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 0.7% from $7.53.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$7.48$7.46$7.34$7.47$7.53-0.7%
    Fiscal year ending Dec 31, 2027$7.16$7.26$6.65$6.77$6.97+2.6%
    Quarter ending Mar 31, 2027$1.62$1.56$1.56$1.54$1.53+5.6%

    Frequently Asked Questions About COLL

    What is the COLL stock forecast?

    Consensus analyst estimates put Collegium Pharmaceutical's EPS at $7.48 for the fiscal year ending Dec 31, 2026, on revenue of $831.97M. The consensus rating from 8 analysts is Buy.

    How do analysts rate COLL stock?

    Of 8 analysts covering Collegium Pharmaceutical, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from COLL next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $7.48, with estimates from $7.30 to $7.60 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $7.16, with estimates from $5.06 to $8.16 from 7 analysts.

    What revenue do analysts expect from Collegium Pharmaceutical next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $831.97M, with estimates from $826.10M to $834.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $847.70M, with estimates from $748.50M to $888.10M.

    How many analysts cover COLL?

    8 analysts rate Collegium Pharmaceutical stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.